Login
One World Products Inc logo

One World Products Inc

oneworldproducts.com

One World Products Inc (OTC: OWPC) is a cannabis and hemp company that has been winding down its Colombian cultivation and processing operations while pivoting toward U.S. retail sales of CBD products. The company's revenue model is transactional, based on direct online sales of white-labeled CBD goods sourced through a strategic partnership. Its primary Colombian subsidiary, OWP SAS, entered judicial liquidation proceedings effective October 1, 2024, under Colombian Law 1116 of 2006, leaving the U.S. CBD retail operation as the remaining active business. In March 2024, the company began selling a white-labeled CBD product called Pro-11, sourced from Stephen Marley's Kx Family Care, with an initial purchase of 2,000 units. A second Colombian entity, Pétalo Pharmaceutical, acquired in May 2024 for its cannabis cultivation and export licenses, was dissolved in Q4 2024, resulting in $75,000 of impairment expense. Net cash used in operating activities was $1,121,637 for the year ended December 31, 2024. The company is led by Dr. Kenneth Perego, II and Terry Buffalo, as indicated in the FY2024 10-K filed June 3, 2025.

Products & Services

Pro-11 white-labeled CBD products sold online in the United States (launched March 2024). Previously held Colombian cannabis cultivation and export licenses through Pétalo Pharmaceutical (dissolved Q4 2024) and OWP SAS (in judicial liquidation as of October 1, 2024).

Revenue Model

Transactional online sales of white-labeled CBD products (Pro-11 brand), sourced from Kx Family Care under a strategic partnership. Prior revenue came from Colombian cannabis cultivation and processing operations, which are now in liquidation as of October 1, 2024.

Customers & Markets

End consumers purchasing CBD wellness products online in the United States. No customer concentration data disclosed in the FY2024 10-K filing.

Geographic Exposure

United States (active CBD product sales as of 2024). Colombia (OWP SAS in judicial liquidation; Pétalo Pharmaceutical dissolved Q4 2024).

Financial Snapshot

Revenue
TTM
$53.42K
Gross Margin
TTM
85.45%
Net Income
TTM
$4.110M
Current Assets
2025 Q3
Current Liabilities
2025 Q3
Current Ratio
2025 Q3
7.15%
Total Assets
2025 Q3
Total Liabilities
2025 Q3
Book Value
2025 Q3
-$445.5K
Cash
2025 Q3
P/E
TTM
0.1257
Free Cash Flow
TTM
-$111.4K

Stock Price

Loading...
Market Cap: $516.47 Thousand

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support